Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Rubino

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Antimicrobial Agents and Chemotherapy|July 31, 2024
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infectionsSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2019
Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumoniaSujata M Bhavnani, Li Zhang, Jeffrey P Hammel, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2017
Pharmacological Basis of CD101 Efficacy: Exposure Shape MattersElizabeth A Lakota, Justin C Bader, Voon Ong, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2020
Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 DataElizabeth A Lakota, Scott A Van Wart, Michael Trang, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2020
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation SolutionSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2013
Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumoniaSujata M Bhavnani, Jeffrey P Hammel, Scott A Van Wart, et al.
Open Forum Infectious Diseases|September 4, 2024
Evaluation of Factors Predictive of Efficacy Among Patients With Complicated Urinary Tract Infection and/or Acute PyelonephritisSujata M Bhavnani, Jeffrey P Hammel, Christopher M Rubino, et al.
Antimicrobial Agents and Chemotherapy|February 11, 2010
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis modelStanley C Gill, Christopher M Rubino, Jennifer Bassett, et al.
Antimicrobial Agents and Chemotherapy|November 5, 2014
Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infectionsSujata M Bhavnani, Jeffrey P Hammel, Scott A Van Wart, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infectionsDavid Melnick, Angela K Talley, Vipul K Gupta, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|July 31, 2024
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infectionsSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2019
Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumoniaSujata M Bhavnani, Li Zhang, Jeffrey P Hammel, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2017
Pharmacological Basis of CD101 Efficacy: Exposure Shape MattersElizabeth A Lakota, Justin C Bader, Voon Ong, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2020
Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 DataElizabeth A Lakota, Scott A Van Wart, Michael Trang, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2020
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation SolutionSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2013
Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumoniaSujata M Bhavnani, Jeffrey P Hammel, Scott A Van Wart, et al.
Open Forum Infectious Diseases|September 4, 2024
Evaluation of Factors Predictive of Efficacy Among Patients With Complicated Urinary Tract Infection and/or Acute PyelonephritisSujata M Bhavnani, Jeffrey P Hammel, Christopher M Rubino, et al.
Antimicrobial Agents and Chemotherapy|February 11, 2010
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis modelStanley C Gill, Christopher M Rubino, Jennifer Bassett, et al.
Antimicrobial Agents and Chemotherapy|November 5, 2014
Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infectionsSujata M Bhavnani, Jeffrey P Hammel, Scott A Van Wart, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infectionsDavid Melnick, Angela K Talley, Vipul K Gupta, et al.
Pageof 7